Key result
Beta and Delta spike antigens elicit higher neutralizing antibody activity than original reference strain vaccines.
Why the study?
Current vaccines may reduce severe disease from existing SARS-CoV-2 variants of concern, but variant-specific antigens may be needed to induce optimal immune responses and reduce infection.
Do variant-specific SARS-CoV-2 spike antigens elicit higher neutralizing antibody activity compared to reference strain vaccines?
Population
Preclinical model using SmT1 SARS-CoV-2 spike antigen platform
Comparison
Beta and Delta variant-based antigens vs original reference strain-based vaccine formulations
Design
Preclinical immunogenicity study
Authors
Loading...
Variant-matched antigens may improve neutralization breadth; leaves open whether updated vaccines alter clinical protection or transmission.
Do variant-specific SARS-CoV-2 spike antigens elicit higher neutralizing antibody activity compared to reference strain vaccines?
Variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses against arising SARS-CoV-2 variants.
Akache et al. (2022) studied SARS-CoV-2. Beta and Delta variant-specific SARS-CoV-2 spike antigens (SmT1v3-B, SmT1v3-D) vs. Reference strain spike antigen (SmT1v3-R) was evaluated on Neutralizing antibody activity against corresponding variants. SARS-CoV-2 spike antigens derived from Beta and Delta variants elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: